40.66
+0.45(+1.12%)
Currency In USD
| Previous Close | 40.21 |
| Open | 40.63 |
| Day High | 40.94 |
| Day Low | 38.66 |
| 52-Week High | 41.5 |
| 52-Week Low | 5.83 |
| Volume | 241,644 |
| Average Volume | 413,596 |
| Market Cap | 1.7B |
| PE | 2.89 |
| EPS | 14.05 |
| Moving Average 50 Days | 31.66 |
| Moving Average 200 Days | 17.15 |
| Change | 0.45 |
If you invested $1000 in Zenas BioPharma, Inc. (ZBIO) since IPO date, it would be worth $2,262.66 as of December 14, 2025 at a share price of $40.66. Whereas If you bought $1000 worth of Zenas BioPharma, Inc. (ZBIO) shares 6 months ago, it would be worth $4,078.23 as of December 14, 2025 at a share price of $40.66.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis
GlobeNewswire Inc.
Oct 27, 2025 11:05 AM GMT
- Obexelimab met primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo, p=0.0009 - WALTHAM, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the
Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million
GlobeNewswire Inc.
Sep 02, 2025 11:05 AM GMT
- Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related Disease - - Additional $150 million associated with the upcoming results of the obexelimab Phase 3 INDIGO trial and FDA approval for th
Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences
GlobeNewswire Inc.
Aug 26, 2025 11:05 AM GMT
WALTHAM, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformat